儿童头颈部放疗后面部变形的系统综述:呼吁标准化结局评估与剂量-效应证据
该系统综述检索PubMed和EMBASE,纳入25项研究、1155例0-18岁头颈部肿瘤患儿,评估放疗后面部变形(FD)的评估方法、患病率和剂量-效应。FD患病率可计算者为21%-97%,评估方法与分级标准差异很大;8项剂量-效应研究中有7项将24-40 Gy剂量范围及治疗时年龄<5-7岁与FD风险相关联。综述呼吁标准化评估工具和分级标准。
要点
- 儿童头颈部放疗后面部变形患病率可计算者为21%-97%,评估方法与分级标准差异很大。
- 8项剂量-效应研究中有7项将24-40 Gy剂量范围与FD风险相关联。
- 治疗时年龄<5-7岁也与FD风险相关,但肿瘤部位和治疗方案异质性限制可比性。
核心结论
- 儿童头颈部放疗后面部变形的评估方法与分级标准差异很大,患病率可计算者为21%-97%,需要标准化评估工具和分级标准以支持稳健的剂量-效应分析。
研究设计与样本
- 系统综述检索PubMed和EMBASE,纳入25项研究,报告1155例1965-2022年间治疗、0-18岁头颈部肿瘤患儿,中位队列样本量24例(范围6-192),治疗/诊断中位年龄4.9岁。
- 纳入标准为全队列平均放疗后>2年报告面部变形,研究使用Cochrane儿童肿瘤偏倚风险工具评估。
主要发现
- 面部变形评估方法分为客观测量和临床报告两类,客观测量再分为头影测量(2D图像)、外部表面(3D)和内部解剖(3D),临床报告包括临床医生报告和患者报告结局。
- 测量和分级标准差异很大,可计算时面部变形患病率为21%-97%。
- 8项剂量-效应研究中有7项将24-40 Gy剂量范围与面部变形风险相关联,治疗时年龄<5-7岁也与风险相关。
- 肿瘤部位和治疗方案异质性限制可比性,面部变形位置和严重程度数据有限制约剂量-效应研究。
关键数值与推荐
- 纳入标准:全队列平均放疗后>2年报告面部变形,患儿0-18岁、因头颈部肿瘤接受治疗。
- 8项剂量-效应研究中有7项将24-40 Gy剂量范围与面部变形风险相关联。
- 治疗时年龄<5-7岁与面部变形风险相关。
临床怎么用
- 临床报告儿童头颈部放疗后面部变形时需关注评估方法和分级标准的差异,当前证据支持24-40 Gy剂量范围和治疗时年龄<5-7岁与风险相关。
- 需采用能同时捕捉面部变形位置和严重程度的标准化评估工具与分级标准,以改善临床报告并支持未来稳健的剂量-效应分析。
局限性
- 肿瘤部位和治疗方案异质性限制可比性。
- 面部变形位置和严重程度数据有限,制约剂量-效应研究。
- 测量和分级标准差异很大,影响患病率与结局的可比性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiation therapy (RT) is an essential treatment modality for paediatric head and neck (HN) cancer, but irradiation during craniofacial development can cause dentofacial side effects, including facial deformation (FD). This systematic review evaluates the evidence on FD post-RT, including assessment methods, prevalence, and dose-response. A literature search was conducted in PubMed and EMBASE. Studies were included if they reported FD > 2 years post-RT on average across the whole cohort in children treated for HN cancer aged 0-18 years. Studies were assessed using the Cochrane Childhood Cancer Risk of Bias tool. Of 2766 articles identified, 25 met the inclusion criteria, reporting on 1155 children treated between 1965 and 2022 (median cohort size: 24, range: 6 - 192) participants. Median age at treatment/diagnosis was 4.9 years. FD assessment methods were analysed in two categories: objective measures and clinical reporting. Objective measures were further categorised: 1) cephalometric (2D image), 2) external surface (3D), 3) internal anatomy (3D). Clinical reporting included clinician-reported and patient-reported outcomes. Measurement and grading criteria varied considerably. Where it could be calculated, prevalence of FD was between 21% and 97%. In seven of the eight studies which examined dose-response, a range of doses between 24-40 Gy was linked to risk of FD, as was age < 5-7 years at the time of treatment. However, heterogeneity in tumour sites and treatment regimens limited comparability. Additionally, limited data on FD location and severity constrained dose-response study. This review highlights the need for standardised assessment tools and grading criteria that captures both location and severity of FD. Such standardisation would improve clinical reporting and support robust dose-response analysis in future research.
引用
- Davey A, Chen Davies LS, Pan S, et al. Systematic review of facial deformation following paediatric head and neck radiation therapy: A call for standardised outcome assessment and dose-response evidence. Radiother Oncol. 2026. PMID: 41722821. doi:10.1016/j.radonc.2026.111448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。